Pusat Ebook Kedokteran :
Recent Ebook
Tampilkan postingan dengan label farmakologi. Tampilkan semua postingan
Tampilkan postingan dengan label farmakologi. Tampilkan semua postingan

Handbook Drugs For Tropical Parasit Infections

The second edition of Handbook of Drugs for Tropical Parasitic Infections is a product from the Unit of Tropical Pharmacology at the Department of Clinical Pharmacology, Huddinge University Hospital. The unit is a collaborative venture between the Departments of Infectious Diseases and Clinical Pharmacology, and
the Hospital Pharmacy. Our department has been involved for many years in research on drugs used in the treatment of tropical parasitic infections. The emphasis has been to develop and apply new bioanalytical techniques to study the clinical pharmacokinetics and metabolites of old and new drugs. Research fellows from Africa, Asia, and South America have participated in this work giving us important feedback from areas where tropical diseases are endemic. Dr Yakoub Aden Abdi from Somalia is one of these past fellows who has devoted his research on the reevaluation of old antiparasitic drugs. It is an honour that he and his Swedish colleagues asked me to write this Preface.
{[['']]}

Management of Diabetes Melitus

Our mentor, the late Dr. Robert L. Jackson, felt that the treatment of diabetes should be as physiologic as possible, matching the treatment to the actual functioning of the pancreas. He determined that patterns, even those obtained with the archaic use of urine tests, were useful in determining the correct dose of medication to cover the food and activity of the active child (and adult). As machines are now made available to match the body’s functioning release of insulin in real time, and the blood glucose levels after a period of time, knowledge of these values will be useful in directing the algorithms used in the pump, the artificial pancreas, or the injected or oral diabetes medications. A rapid, reactive response is needed when the person is in diabetic ketoacidosis (DKA), in hyperglycemic hyperosmolar nonketotic syndrome (HHNS), or having a severe hypoglycemic reaction. Daily use of diabetes medications to maintain a hemoglobin A1c lower than 6.5% (American Diabetes Association, 7%) does not need to be as dramatic, especially when the decision making is done by the patient or family member. The physiologic or pattern approach to management not only gives a safety factor, but also has proven quite useful in maintaining a high degree of control over long periods of time (evidence by the average, from the worst to the best hemoglobin A1c in our tertiary care diabetes clinic, is 7.4%). As a tertiary care clinic, we get individuals with newly diagnosed diabetes, people who are failing on oral agents, people who have already developed complications, and others that are difficult to control. We therefore have had extensive experience with numerous patients for more than 40 years. We have attempted to put our years of experience in this book and to make this book user friendly for a variety of health professionals. Although the first edition was written as a guide for the working nurse who cared for a patient with diabetes, we recognized, over the years, that the book has become a working
reference for all health professionals, including those professionals specializing in the field, and as a textbook for professionals wanting to know more about the disease and how to manage it by using the pattern approach. I am reminded of an airplane ride in which I became involved in a conversation with a physician seated close by. During the course of the conversation I found that she was using our book as a guide for managing patients with diabetes. When I disclosed that I was one of the authors, tears welled up in her eyes
and she thanked me for the help it had given her and her patient population. When Richard and I discovered that some physicians, in addition to nurses and other health professionals, were using this book, we decided to develop the edition for broader use and for better ease of use. What you will find in the
proceeding pages is the result.
{[['']]}

Therapeutic Strategies in Metabolic Syndrome

We are in the midst of a worldwide epidemic of obesity and its consequences, in particular type 2 diabetes and cardiovascular disease. Clinical studies have recognized that risk factors for these conditions frequently cluster in individuals, leading to the development of the concept of the metabolic syndrome. This was soon followed by considerable controversy as to whether the syndrome is a distinct entity or not. In addition, multiple definitions and diagnostic criteria have made interpretation of data occasionally problematic. I expect that this controversy will continue, though all parties on both sides of the argument are clearly in agreement on one thing – we need action to halt the progression from risk factor development to clinical events and death. Despite the controversies on terminology, therefore, it is important to focus on the goal of effective treatment, hence the development of this book. Although our goal is to have an in-depth analysis of treatment strategies, we felt it important to first review the epidemiology and pathophysiology of the syndrome, in order to lay the groundwork for developing treatment concepts. We have also strongly emphasized the importance of lifestyle (and perhaps societal) change that is needed to halt this epidemic. Clearly, preventing and treating obesity effectively should liberate us from the syndrome. However, whether we use population strategies or individualized pharmacotherapy for obesity, the greatest impact is likely to be seen in treatments that alleviate risk factors involved in the pathogenesis of cardiovascular events such as blood pressure, lipids, inflammation
and thrombogenesis. To that end, we have focused on the impact of treatment on these factors. It is also important to recognize the impact of current treatments for individual risk factors on other components of the syndrome. This is most clearly recognizable in the effect of glucose-lowering drugs, particularly insulin sensitizers if insulin resistance is an important underlying feature of the syndrome. Some of these drugs, as well as insulin itself, paradoxically cause weight gain, yet favorably impact other features of the syndrome. Is that good or bad? The answers are currently surrounded by controversy, the essence of which we hope we have captured adequately in the text. We look forward to further clarification from ongoing clinical trials. I am most grateful to the outstanding group of authors who have contributed scholarly and up-to-date reviews in a timely fashion. Finally, I would like to dedicate this book to the city of New Orleans and to its fragile
recovery from disaster.

Vivian Fonseca
June 2008
{[['']]}

Basic and Clinical Pharmacology Katzung

this book is designed to provide a complete and current and readable pharmacology textbook for student in medicine. so grab it fast!
{[['']]}

Handbook of Psychiatric Drugs


There is little question that this is the most exciting time in history to be involved in the treatment of patients with psychiatric disorders. The explosive growth in our knowledge base in all areas of the field, particularly in neuroscience, has revolutionized both our understanding of the nature of psychiatric illnesses and our ability to provide effective treatments. As molecular genetics and pharmacology, neurochemistry,
and new drug discovery techniques continue to advance, physicians are faced with the need to assimilate an everchanging body of knowledge. In particular, the change in pharmacotherapy for psychiatric illnesses continues at a dizzying pace. We have been very gratified by the extremely positive international
response to our major textbook, Psychiatry, Second Edition (Tasman, A, Kay, J, Lieberman, JA, Wiley, 2003). We believe, however, that busy clinicians need a quick reference guide to the most up-to-date information on prescribing medications for psychiatric illnesses. This book, the Handbook of Psychiatric Drugs, is based on the outstanding chapters on pharmacotherapy in Psychiatry, Second Edition. The material has been condensed, updated to just months before publication, and organized by specific classes of medications. To enhance the daily utility of this handbook, we chose a format that emphasized ease of use, and ensured that each chapter follows a specific template of topics, including the pharmacology, mechanism of action and pharmacokinetics, indications and methods of prescribing, side effects and drug
interactions, and descriptions of each specific drug within the class. We have aimed to include prescription medications in common use anywhere in the world. Further, each chapter was then reviewed by highly respected psychiatrists with pharmacotherapy expertise in that particular class of medication.

{[['']]}

Handbook of Drugs for tropical Infections


The second edition of Handbook of Drugs for Tropical Parasitic Infections is a product from the Unit of Tropical Pharmacology at the Department of Clinical Pharmacology, Huddinge University Hospital. The unit is a collaborative venture between the Departments of Infectious Diseases and Clinical Pharmacology, and
the Hospital Pharmacy. Our department has been involved for many years in research on drugs used in the treatment of tropical parasitic infections. The emphasis has been to develop and apply new bioanalytical techniques to study the clinical pharmacokinetics and metabolites of old and new drugs. Research fellows from Africa, Asia, and South America have participated in this work giving us important feedback from areas where tropical diseases are endemic. Dr Yakoub Aden Abdi from Somalia is one of these past fellows who has devoted his research on the reevaluation of old antiparasitic drugs. It is an honour that he and his Swedish colleagues asked me to write this Preface. During the past 40 years novel drugs have been introduced for diseases that were in the past the cause of death of thousands of people. Advances in the field
of clinical pharmacology have contributed to a safer and more effective use of both old and new drugs and thereby to better patient care. In particular, new knowledge about genetic and environmental determinants of drug metabolism in humans has made it possible to introduce rational strategies in drug treatment. Pharmacoepidemiology, a science concerned with epidemiological aspects of the safety and efficacy of drug products and their utilization in the population, has also grown in importance in recent years. Developed and less developed countries seem to share a number of problems leading to irrational drug use such as old fashioned teaching in pharmacology, drug information that is productrather than problem-oriented and increasing criticism among patients and politcians about how drugs are being prescribed by physicians.
{[['']]}

Goodman and Gilmans Pharmacological


Upon learning that I was assuming the editorship of this book, a senior colleague warned, "Be careful. Don't tamper lightly with the bible." This reputation of "G & G" as the "bible of pharmacology" is a tribute to the ideals and writing of the original authors, Alfred Gilman and Louis Goodman. In 1941, they set forth the principles that have guided this book through ten prior editions and that the associate editors and I have continued to use: to correlate pharmacology with related medical sciences, to re-interpret the actions and uses of drugs in light of advances in medicine and the basic biomedical sciences, to emphasize the applications of pharmacodynamics to therapeutics, and to create a book that will be useful to students of pharmacology and physicians alike.

As with all editions since the second, expert scholars have written the individual chapters, a number of which are new to this edition. We have emphasized basic principles, adding chapters on drug transporters and drug metabolism; the material covered in these chapters explains many prominent drug-drug interactions and adverse drug responses. We have also added a chapter on the emerging field of pharmacogenetics, looking toward the individualization of therapy and an understanding of how our genetic make-up influences our responses to drugs. A chapter entitled "The Science of Drug Therapy" describes how basic principles of pharmacology apply to the care of the individual patient. Most other chapters have been extensively revised; a few have been condensed or eliminated.

Assembling a multi-author pharmacology book challenges contributors and editors in different ways. Among the apparently irresistible and understandable temptations in writing a chapter are the desire to cover everything, the urge to explain G-protein coupled signaling, and the inclination to describe in detail the history of the field in which one is an expert, citing all relevant papers from Claude Bernard to the present. These hazards, plus the continuing advance of knowledge, produce considerable pressure to increase the length of the book. As an antidote, the associate editors and I have worked to eliminate repetition and extraneous text. We have pressed contributors hard, using the communicative rapidity and ease of e-mail to interact with them, to clarify and condense, and to re-write while adhering to the principles of the original authors and retaining the completeness for which the book is known. We have tried to standardize the organization of chapters; thus, students should easily find the physiology and basic pharmacology set forth in regular type in each chapter, and the clinician and expert will find details in extract type under identifiable headings. We have also tried to improve the clarity of tables and figures to provide summaries of concepts and large amounts of information. Although this 11th edition is slightly shorter than its predecessor, we believe that it is every bit as thorough.

Many deserve thanks for their contributions to the preparation of this edition. Professors Keith Parker (UT Southwestern) and John Lazo (U. Pittsburgh) have lent their considerable energy and expertise as associate editors. Professor Nelda Murri (U. Washington) has read each chapter with her keen pharmacist's eye. Two Nashville novelists played essential roles: Lynne Hutchison again served ably as managing editor, coordinating the activities of contributors, editors, and word processors; and, for the second time, Chris Bell checked references and assembled the master copy. Each chapter has been read by an expert in addition to the editors, and the editors thank those readers. We also express our appreciation to former contributors, who will, no doubt, recognize some of their best words from previous editions. We are grateful to our editors at McGraw-Hill, Janet Foltin and James Shanahan, who have shepherded the edited text into print, and to our wives, whose support and forbearance are gifts beyond reckoning. Lastly, I would like to pay tribute to my friend, Alfred G. Gilman. As a teacher, mentor, researcher, editor of several editions of this book, Nobel laureate, chair of a distinguished pharmacology department, and now dean of a medical school, he has enriched every aspect of our field.

Laurence Brunton
SAN DIEGO, CALIFORNIA
JULY 1, 2005

{[['']]}

Pocket Clinical Drug Reference


Davis’s Pocket Clinical Drug Reference is a quick resource for the most commonly used drugs in clinical practice. The monographs are designed to highlight pertinent information; specifically, each monograph
includes a drug’s generic name, brand name, therapeutic indication, pharmacologic class, pregnancy class, contraindications, adverse drug reactions, drug interactions, dose, availability, and monitoring
parameters. To incorporate as many drugs as possible into a pocket drug guide format, only the most common adverse drug reactions and drug interactions are presented within each monograph. The table entitled Cytochrome P450 Substrates/Inhibitors/Inducers (page 285) provides more specific information regarding the drugs that may be involved in certain drug interactions. Additionally, within each monograph, a Notes section is included to highlight miscellaneous information that users should consider when initiating or monitoring drug therapy in their patients. In the Appendix, a number of useful tables and charts, covering
topics such as immunization guidelines, intravenous drugs, and narcotic equianalgesic dosing guidelines, provide additional information that is relevant to clinical practice. To obtain detailed drug information beyond what is supplied in the monographs of this pocket drug guide, the user should refer to the medical literature or the complete product information supplied by the manufacturer.

{[['']]}
 
Support : dokter desa | Design Template | ibank
Copyright © 2011. Ebook Kedokteran - All Rights Reserved
Template Edited by Medical Virtual Multimedia Published by dokter desa
Proudly powered by Blogger